Comparative Study of the Efficacy and Side Effects of Brand-Name and Generic Clozapine for Long-Term Maintenance Treatment Among Korean Patients With Schizophrenia: A Retrospective Naturalistic Mirror-Image Study

키워드

참고문헌 (63)

1. Solanki RK, "Current perspectives in the treatment of resistant schizophrenia", Indian J Psychiatry, 51, pp.254~260 (2009)
2. Khokhar JY, "Unique effects of clozapine : a pharmacological perspective", Adv Pharmacol, 82, pp.137162~ (2018)
3. Crilly J, "The history of clozapine and its emergence in the US market : a review and analysis", Hist Psychiatry, 18, pp.39~60 (2007)
4. Hippius H, "A historical perspective of clozapine", J Clin Psychiatry, 60(Suppl 12), pp.22~23 (1999)
5. Asenjo Lobos C, "Clozapine versus other atypical antipsychotics for schizophrenia", Cochrane Database Syst Rev, 11, pp.CD006633~ (2010)
6. Meltzer HY, "Treatment-resistant schizophrenia--the role of clozapine", Curr Med Res Opin, 14, pp.1~20 (1997)
7. "Clozapine"[URL]
8. Kane J, "Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorproma zine", Arch Gen Psychiatry, 45, pp.789~796 (1988)
9. Dold M, "Pharmacotherapy of treatment-resistant schizophre nia : a clinical perspective", Evid Based Ment Health, 17, pp.33~37 (2014)
10. Hasan A, "World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for biological treatment of schizophrenia, part 1 : update 2012on the acute treatment of schizophrenia and the management of treat ment resistance", World J Biol Psychiatry, 13, pp.318~378 (2012)
11. Buchanan RW, "The 2009 schizophrenia PORT psychopharmacological treat ment recommendations and summary statements", Schizophr Bull, 36, pp.71~93 (2010)
12. Lehman AF, "Practice guideline for the treatment of patients with schizophrenia, second edition", Am J Psychiatry, 161(2 Suppl), pp.1~56 (2004)
13. Miller DD, "Review and management of clozapine side effects", J Clin Psychiatry, 61(Suppl 8), pp.14~17 (2000)
14. Bellissima BL, "A system atic review of clozapine-induced myocarditis", Int J Cardiol, 259, pp.122~129 (2018)
15. Zimbron J, "A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome", Eur Neuropsychopharmacol, 26, pp.1353~1365 (2016)
16. Slim M, "Hepatic safety of atypical antipsychotics : current evidence and future directions", Drug Saf, 39, pp.925~943 (2016)
17. Taylor DM, "The Maudsley prescribing guide lines in psychiatry" (2021), John Wiley & Sons
18. Lindström LH, "The effect of long-term treatment with clozapine in schizophrenia : a retrospective study in 96 patients treated with clozap ine for up to 13 years", Acta Psychiatr Scand, 77, pp.524~529 (1988)
19. Juul Povlsen U, "Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years", Acta Psychiatr Scand, 71, pp.176185~ (1985)
20. Wong J, "A sys tematic review on the use of clozapine in treatment of tardive dyskine sia and tardive dystonia in patients with psychiatric disorders", Psycho pharmacology(Berl), 239, pp.3393~3420 (2022)
21. Meltzer HY, "Clozapine treatment for suicidality in schizophrenia : international suicide prevention trial(InterSePT)", Arch Gen Psychiatry, 60, pp.8291~ (2003)
22. Fischer MA, "Economic consequences of underuse of generic drugs : evidence from Medicaid and implications for prescription drug benefit plans", Health Serv Res, 38, pp.1051~1063 (2003)
23. Chisholm D, "Schizophrenia treatment in the developing world : an interregional and multinational cost-effectiveness analysis", Bull World Health Organ, 86, pp.542~551 (2008)
24. "Dongwha releases schizophrenia drug ‘Clzapine’... First local ization success"[URL]
25. Woo YS, "Bioequiva lence of generic and brand name clozapine in Korean schizophrenic patients : a randomized, two-period, crossover study", Psychiatry Inves tig, 12, pp.356~360 (2015)
26. Desmarais JE, "Switching from brand-name to generic psychotropic medications : a literature review", CNS Neurosci Ther, 17, pp.750~760 (2011)
27. Atif M, "Potential problems and recommenda tions regarding substitution of generic antiepileptic drugs : a systematic review of literature", Springerplus, 5, pp.182~ (2016)
28. Lam YW, "Branded versus gener ic clozapine : bioavailability comparison and interchangeability issues", J Clin Psychiatry, 62(Suppl 5), pp.18~22 (2001)
29. Bobo WV, "Convert ing from brand-name to generic clozapine : a review of effectiveness and tolerability data", Am J Health Syst Pharm, 67, pp.27~37 (2010)
30. Paton C, "Generic clozapine : outcomes after switching formulations", Br J Psychiatry, 189, pp.184~185 (2006)
31. Alvarez CA, "Increasing psychosis in a patient switched from clozaril to generic clozapine", Am J Psychiatry, 163, pp.746~ (2006)
32. Kluznik JC, "Clinical effects of a randomized switch of patients from clozaril to generic clozapine", J Clin Psychiatry, 62(Suppl 5), pp.14~17 (2001)
33. Mofsen R, "Case reports of the reemergence of psychotic symp toms after conversion from brand-name clozapine to a generic formu lation", Clin Ther, 23, pp.1720~1731 (2001)
34. Gardner DM, "International consensus study of antipsychotic dosing", Focus, 12, pp.235~243 (2014)
35. Inada T, "Psychotropic dose equivalence in Japan", Psychiatry Clin Neurosci, 69, pp.440~447 (2015)
36. Hayasaka Y, "Dose equivalents of antidepressants : evidence-based recommen dations from randomized controlled trials", J Affect Disord, 180, pp.179184~ (2015)
37. Subramanian S, "Clozapine dose for schizophre nia", Cochrane Database Syst Rev, 6, pp.CD009555~ (2017)
38. Nielsen J, "Optimizing clozapine treat ment", Acta Psychiatr Scand, 123, pp.411~422 (2011)
39. Murphy B, "Maintenance doses for clozapine", Psychiatr Bull, 22, pp.12~14 (1998)
40. Sharma A, "Maintenance doses for clozapine : past and present", BJPsych Bull, 42, pp.217~ (2018)
41. Ruan CJ, "Clozapine metabolism in East Asians and Caucasians : a pilot exploration of the prevalence of poor metabolizers and a systematic review", J Clin Psychopharmacol, 39, pp.135~144 (2019)
42. de Leon J, "Do Asian patients require only half of the clozapine dose pre scribed for Caucasians? A critical overview", Indian J Psychol Med, 42, pp.4~10 (2020)
43. Kang N, "Association be tween initial pattern of clozapine titration, concentration-to-dose ratio, and incidence of fever in patients with schizophrenia spectrum disor ders in a Korean tertiary hospital", Schizophr Res (2023)[DOI]
44. Wang C, "Proper use of clozapine : experiences in China", Shanghai Arch Psychiatry, 24, pp.108~109 (2012)
45. Inada K, "Analysis of clozapine use and safety by using comprehensive national data from the Japanese clozapine patient monitoring service", J Clin Psychopharmacol, 38, pp.302~306 (2018)
46. Shrivastava A, "Prescribing practices of clozapine in India : re sults of a opinion survey of psychiatrists", Indian J Psychiatry, 51, pp.225226~ (2009)
47. Ng CH, "An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels", Int Clin Psychopharmacol, 20, pp.163~168 (2005)
48. Spina E, "Clinical applications of CYP genotyping in psychia try", J Neural Transm(Vienna), 122, pp.5~28 (2015)
49. Grover S, "Clinical practice guide lines for management of schizophrenia", Indian J Psychiatry, 59(Sup pl 1), pp.S19~S33 (2017)
50. Wheeler AJ, "Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand", Ann Pharmacother, 42, pp.852860~ (2008)
51. Harrison J, "Patterns of clozapine prescribing in a mental health service in New Zealand", Pharm World Sci, 32, pp.503511~ (2010)
52. Tungaraza TE, "Prescribing pattern of clozapine and other antipsychotics for pa tients with first-episode psychosis : a cross-sectional survey of early in tervention teams", Ther Adv Psychopharmacol, 7, pp.103~111 (2017)
53. Yi W, "Clozapine use in patients with early-stage schizophrenia in a Chinese psychiatric hospital", Neuropsychiatr Dis Treat, 16, pp.2827~2836 (2020)
54. Verdoux H, "Clozapine use pattern in persons with and without treatment for Parkinson’s disease in real-world conditions : a naturalistic study in a community-based sample", Acta Psychiatr Scand, 130, pp.487~497 (2014)
55. Bartoli F, "Adjunctive second-generation antipsychotics for specific symp tom domains of schizophrenia resistant to clozapine : a meta-analysis", J Psychiatr Res, 108, pp.24~33 (2019)
56. Siskind DJ, "Augmentation strategies for clozapine refractory schizophrenia : a sys tematic review and meta-analysis", Aust N Z J Psychiatry, 52, pp.751~767 (2018)
57. Galling B, "Antipsychotic augmentation vs. monotherapy in schizophrenia : sys tematic review, meta-analysis and meta-regression analysis", World Psychiatry, 16, pp.77~89 (2017)
58. Mao YM, "Augmentation with antidepressants in schizo phrenia treatment : benefit or risk", Neuropsychiatr Dis Treat, 11, pp.701713~ (2015)
59. Baymiller SP, "Serum glucose and lipid changes during the course of clozapine treatment : the effect of concurrent beta-adrenergic antagonist treatment", Schizophr Res, 59, pp.49~57 (2003)
60. Henderson DC, "Clozapine, diabetes mellitus, hyperlipidemia, and car diovascular risks and mortality : results of a 10-year naturalistic study", J Clin Psychiatry, 66, pp.1116~1121 (2005)
61. Lamberti JS, "Prevalence of the metabolic syndrome among patients receiving clo zapine", Am J Psychiatry, 163, pp.1273~1276 (2006)
62. Strom BL, "Generic drug substitution revisited", N Engl J Med, 316, pp.1456~1462 (1987)
63. Al-Jazairi AS, "Brand and ge neric medications : are they interchangeable?", Ann Saudi Med, 28, pp.33~41 (2008)

관련 논문AI추천